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Introduction 
The term peripheral neuropathy encompasses a 
wide range of disorders. The underlying causes of 
peripheral neuropathy are diverse. It is very difficult to 
ascertain the incidence of peripheral neuropathy with 
any degree of certainty, but it is a manifestation of 
several common multisystem disorders, whose incidence 
is on the rise, such as diabetes and Human 
Immunodeficiency (HIV) virus infection. Worldwide, 
the population prevalence is about 2,400 per 100,000 
(2.4%), rising with age to 8,000 per 100,000 (8%).1 
Peripheral neuropathy can significantly impact an 
individual's quality of life especially if undiagnosed and 
untreated. 
Investigation of peripheral neuropathy is expensive 
and time consuming, and is best performed in a stepwise 
approach. Even in the best of circumstances, an 
aetiological diagnosis is not always achieved. At present, 
the existing guidelines deal with the treatment of 
peripheral neuropathy but there are none on how patients 
with peripheral neuropathy should be investigated. 
 
Aims of the audit 
The aims were to assess how patients in Mater Dei 
Hospital were investigated for peripheral neuropathy and 
whether a definite diagnosis was ultimately reached. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methodology 
Patient Population and Data Collection 
Approval was obtained from the data protection 
officer at Mater Dei Hospital. 536 EMG results from the 
year 2011 were randomly selected from the database of 
the Neuroscience department. These were reviewed and 
the patients with a neurophysiological diagnosis of 
peripheral neuropathy were identified. The 
investigations performed within a year, before or after, 
the EMG date for these patients were studied. 
Demographics, source of referral, indication for EMG 
and diagnostic data were collected for each patient, 
using PACS, Isoft Clinical Management, Electronic 
Case Summary, and patient’s records. All the data was 
inputted in a tabulated format using Excel and then 
analysed. 
In this audit, Complete blood count (CBC), Renal 
profile, Calcium, Liver profile, Fasting blood glucose 
(FBG) or haemoglobin A1c (Hba1c), Thyroid function 
tests, vitamin B12, urinalysis for microscopy and Chest 
X-ray were considered to be first line investigations. 
Second line investigations include HIV serology, 
vasculitic screen, serum protein electrophoresis (SPE) 
and tumour markers, and ultrasound of the abdomen. 
Serum Angiotensin Converting Enzyme (ACE) levels, 
paraneoplastic panel, anti ganglioside antibodies, 
Cerebrospinal fluid (CSF) analysis, nerve biopsy and 
genetic testing were considered to be specialised tests 
[Table 1]². 
 
Results 
118 patients with a neurophysiological diagnosis of 
a peripheral neuropathy were identified from the first 
536 EMG results of the year 2011. From the total of 118 
patients with peripheral neuropathy, 116 were selected 
for further review. 
44 patients (37.3%) were female and the remaining 
62.7% were male (n= 74). The mean age was 59.3 years 
with a range of 4-86 years. 
When looking at the remaining 418 EMG results: 
34% (n=182) were reported as normal, 40.7% were 
reported as mononeuropathy (n=218), 0.6% plexopathy 
(n=3), radiculopathy in 0.4% (n=2), anterior horn cell 
disease in 0.4% (n=2) and myopathy in 0.4% (n=2). 
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Table 1: Summary of investigations for peripheral neuropathy 
 
 
 
History 
And 
Examination  
First tier  CBC, renal profile, liver profile, calcium, 
FBG/Hba1c, ESR, TFTs, B12 levels, urinalysis, 
CXR  
Second tier  Vasculitic screen, HIV serology, SPE, tumour 
markers, US abdomen  
Third tier  ACE levels, paraneoplastic panel, anti-ganglioside 
antibodies, CSF analysis, nerve biopsy and genetic 
testing  
 
The commonest indication for the 536 EMG tests 
was mononeuropathy (53.9%, n= 290) followed by 
peripheral neuropathy in 24.4% (n=131).  The 
commonest mononeuropathy diagnosed was carpal 
tunnel syndrome (41%). In a number of cases more than 
one indication was selected for the EMG. Peripheral 
neuropathy was most commonly combined with carpal 
tunnel syndrome (3.7%). 
With regards to the peripheral neuropathy cohort, 
the main source of referral was the department of 
Neuroscience (61%, n=72). The other two major sources 
of referral were the department of Medicine with 16.1% 
(n= 19) and the Orthopaedics department with 13.6% 
(n= 16). 47.4% of EMGs booked from the department of 
medicine were from the diabetes clinic. Of note 6 
patients, that were included in this audit, were referred 
from the paediatrics department (5.1%). The remaining 5 
were booked from the Geriatrics department, Gozo 
general hospital, pain clinic and the Department of 
Surgery. 
 
Peripheral Neuropathy Cases 
When looking at the indications for those 116 cases 
with an eventual neurophysiological diagnosis of 
peripheral neuropathy, in 64.4% the main indication was 
in fact peripheral neuropathy. In 16.1% the indication 
was mononeuropathy, 13.57% had a combined 
indication, and the remaining 5.83% were requested for 
suspected cervical myelopathy, trauma, myotonic 
dystrophy, myopathy and critical illness neuropathy. 
 
Investigations 
Co-morbidities that are associated with 
peripheral neuropathy were reviewed for all the 116 
patients. At the time of request of EMG, the commonest 
documented co-morbidity detected was diabetes in 
40.7% of cases followed by malignancy in 9.3% and  
 
 
 
drugs in 5.9%. Other relevant known co-
morbidities at time of request included advanced chronic 
kidney disease (3.4%), hepatic cirrhosis (2.5%), 
nutritional e.g. vitamin B12 deficiency (2.4%), 
infectious diseases e.g. HIV (1.2%), endocrine (1.2%) 
and vasculitis (1.2%). In 44.1% no relevant co-
morbidities were identified. The neurology department 
was involved in 58.1% of peripheral neuropathy cases 
(n=68). In the majority of cases this occurred prior to the 
EMG test. 
All the investigations performed on the 116 patients 1 
year before and 1 year after the EMG’s were searched. 
When looking at the first line tests that form part of the 
peripheral neuropathy work-up: a complete blood count 
was found in 94.8% of cases, renal profile in 93.1% of 
cases, serum calcium in 67.2%, FBG/Hba1c in 78.4%, 
LFTs in 88.8%, ESR in 62.1%, TFTs in 83.6% and 
vitamin b12 levels in 60.3%. Urinalysis was available in 
38.8% of patients and a chest x-ray was taken in 54.3% 
of patients. A proportion of these investigations were 
performed after the EMG was done as seen in figures 1 
and 2. 
With respect to the second line investigations anti-
nuclear antibody levels were taken in 41% of patients 
with 58.3% being taken prior the EMG. Anti-nuclear 
cytoplasmic antibody levels were taken in 23% of 
patients only. 63% of these were available up to 1 year 
prior to EMG. Serum protein electrophoresis and tumour 
markers were taken in 46% and 44.4% of patients 
respectively. 53.3% of SPE results and 44.4% of tumour 
marker results were taken before the EMG. An 
ultrasound abdomen was requested in 22.2% of patients 
with 57.6% being done prior the EMG. 
In terms of specialised tests, anti-ganglioside 
antibodies were taken in 18.5% of patients, ACE levels 
in 7% and the paraneoplastic panel in 18.8%. CSF 
analysis was performed in 16 patients (13.7%) and a 
nerve biopsy was taken in 6 patients (5.15%). Genetic 
studies were done for a total of four patients. 
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Figure 1: Results of first tier of investigations 1 year before/after EMG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: First line investigations done prior or after EMG 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Before EMG
After EMG
12
  
 
 
Review Article 
 
 
 
Malta Medical Journal    Volume 27 Issue 03 2015                                                                                                                
 
 
52.50%
16.90%
6.80%
6.80%
5%
12%
Final diagnosis
Diabetic neuropathy
GBS/CIDP
Inherited neuropathy
Critical illness neuropathy
B12 deficiency
Others
Figure 3: Final diagnoses of peripheral neuropathy cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical notes of all 116 patients were reviewed in 
search for a documented diagnosis. Each patient fit in 1 
of 3 possibilities: no data (no documentation at all was 
found relevant to the final diagnosis), no diagnosis 
(patient was investigated but a final diagnosis was not 
achieved) and diagnosis present (aetiological diagnosis 
documented in the medical report). Results showed 11 
cases with no data, 46 with no diagnosis and 59 patients 
with a diagnosis. Diagnoses were diabetic neuropathy 
(n=31), Guillaine-Barre syndrome/ Chronic 
Inflammatory Demyelinating Polyneuropathy (n=10), 
hereditary neuropathies (n=4), critical illness neuropathy 
(n= 4), B12 deficiency (n=3), monoclonal gammopathy 
associated neuropathy (n=3), vasculitic neuropathy 
(n=2) and drug-induced neuropathy (n=2) [Figure 3]. 
 
Discussion 
A definite diagnosis of the aetiology of peripheral 
neuropathy is not always possible. The most common 
generalized polyneuropathy is diabetic sensorimotor 
polyneuropathy together with alcohol related 
neuropathy.3 Thus, history taking is still paramount in 
the work up of this condition as it can give important 
clues as to what the cause may be e.g. concomitant 
diabetes, alcohol abuse and family history of neuropathy. 
Neuropathic pain can cause distress and 
significantly affect the patient’s quality of life. Apart 
from symptomatic treatment, one should aim to direct 
the treatment to the underlying cause. This reinforces the 
need to obtain a diagnosis whenever it is possible. In the  
 
challenging cases where the cause is not apparent from 
the history it is best to adopt a methodological approach. 
Different tiers of investigations ensure that the 
diagnostic process is efficient, rational and cost 
effective. 
In this audit, 22% (N=118) of all the EMG’s 
reviewed were confirmed to be peripheral neuropathy. 
Of note 9 patients in total were referred from the 
diabetes clinic. As expected, the majority (61.4%) were 
referred from the Neuroscience department. Four 
paediatric cases were identified from the cohort. This 
would explain the low mean age observed (59.3 years). 
Peripheral neuropathy was the indication for the test in 
78% of cases. This implies that in the remaining 22% of 
cases the diagnosis was incidental. 
Diabetes mellitus was the commonest co-morbidity 
documented in the cohort. Despite this, a FBG and/ or an 
Hba1c were not taken in 21.4% of patients. An Hba1c is 
still indicated in known diabetics because it can help 
assess diabetic control. Diabetic neuropathy is the 
commonest cause of neuropathy in Western countries 
with up to a third of the direct costs of diabetes 
attributed to neuropathy-related morbidity.4 It may be 
present in up to 66% of type 1 and 59% of type 2 
diabetics making it one of the commonest complications 
of diabetes.3 The EMG can be normal in a diabetic 
patient with peripheral neuropathy symptoms due to 
small fibre neuropathy. In this audit 26.7% of the 
patients were confirmed to have diabetic peripheral 
neuropathy. 
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Baseline investigations such as a complete blood 
count or renal profile grouped in this study as the first 
tier were not taken in all the patients during the 2 year 
time limit preset for this audit. In this audit 39.7% of our 
cohort remained without an aetiological diagnosis. In the 
subset of patients that remained without a diagnosis 
(n=46) only 8 patients (16.3%) had completed the first 
tier of investigations over the 2 year period. In the 
remaining 38 patients several investigations were 
missing: urinalysis missing in 71% (n=27), ESR missing 
in 45% (n=17), vitamin B12 levels missing in 40% 
(n=15), calcium levels missing in 37% (n= 14), 
FBG/HBa1c levels missing in 26% (n=10) and 21% did 
not have a chest x-ray taken (n=8). A complete blood 
count was the only investigation available for all these 
patients. Irrespective of whether these tests would have 
been abnormal or not they are still needed for the 
investigation of peripheral neuropathy. The fact these 
core investigations were missing could reflect the lack of 
a systemic approach adopted when investigating patients 
with peripheral neuropathy.  
It is estimated that about 20% of patients seen at 
peripheral neuropathy clinics are idiopathic despite 
intensive evaluation.5-6 Chronic idiopathic axonal 
polyneuropathy is an entity met in the literature relevant 
to this condition. It is a diagnosis of exclusion, with 
uncertain prevalence.  The cause is not known and is 
probably heterogeneous, but a possible association with 
impaired glucose tolerance or metabolic syndrome has 
been suggested. One study found a closer association 
with hypertriglyceridaemia (a feature of the metabolic 
syndrome) rather than with impaired glucose tolerance.7-
8  This raises the issue whether we should include a lipid 
profile and an oral glucose tolerance test as part of the 
second tier of investigations. It is possible that an 
inherited neuropathy was missed in those 46 patients 
that remained without a diagnosis. However these are 
rare and have an estimated prevalence of one in every 
2500 individuals. 9 
The audit was limited by the fact that we could not 
access results of investigations done within the private 
sector and this could have biased our data. Other clinical 
data such as co-morbidities was not necessarily 
documented in the sources of information that we used. 
Thus we could have underestimated the prevalence of co 
morbidities in our cohort. 
Specialised tests were performed in a significantly 
lower proportion of the patients. This was expected as 
these tests are not indicated in all cases with peripheral 
neuropathy. It was interesting to note that genetic testing 
was performed in 4 patients. One was inconclusive 
whilst the other diagnoses were Facioscapulohumeral 
dystrophy, Charcot-Marie Tooth disease and Myotonic 
dystrophy.  
 
Conclusion 
This audit has shown that there are a significant 
proportion of cases of peripheral neuropathy that remain 
without an aetiological diagnosis. Using a stepwise 
approach which involves a good history and examination 
followed by the recommended investigations can help 
make this process more efficient and facilitate the path 
towards achieving a final diagnosis. Ultimately not all 
patients will have a diagnosis despite being properly 
investigated. On the other hand, not all patients will 
require all the investigations available and this could be 
for numerous reasons such as the diagnosis can be clear 
from the history or the patient may refuse specialised 
tests. 
In a significant proportion of patients in this audit 
the cause of peripheral neuropathy was identifiable from 
the history, examination and the first tier of 
investigations e.g. B12 deficiency. In these situations 
where the cause and management is clear specialist 
referral is not necessary. Of note, 20 out of the total 31 
diabetic neuropathies were still being diagnosed by or 
referred to neurologists. On the other hand, it is wise to 
keep an open mind when investigating peripheral 
neuropathy even in known diabetic patients. 
This audit highlights the significance that a 
thorough history, examination and baseline 
investigations can have in achieving a diagnosis for 
peripheral neuropathy. Such baseline investigations are 
readily available even to general practitioners in the 
community. This will help avoid unnecessary specialist 
referrals. Red flags that warrant referral to a neurologist 
are an uncertain cause, severe symptoms, rapid 
progression as well as the presence of weakness or 
motor symptoms.1   
A re-audit, using a standard proforma based on the 
investigations mentioned, will be done in a prospective 
fashion so as to see whether its implementation can lead 
to an improvement in the diagnostic yield of peripheral 
neuropathies. 
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